期刊文献+

新型生物活性物质尾加压素Ⅱ降眼压作用的实验研究 被引量:1

Experimental study of intraocular pressure decreased by new biological activity substance of Urotensin Ⅱ
下载PDF
导出
摘要 目的:探讨尾加压素Ⅱ(urotensinⅡ,U-Ⅱ)对兔眼压的影响。方法:将10,100pg/μL和1,10ng/μL浓度的U-Ⅱ溶液10μL分别注射到新西兰白兔眼玻璃体前部,于注射后即刻(0h),1,2,4,6,8,10,12,24,36h;2,3,4,5,6d不同时间点,用修兹眼压计行双砝码法眼压测量。结果:0.1ngU-Ⅱ组在10~12h使眼压降低17.5%(P<0.001);1ngU-Ⅱ组在8h使眼压降低33.7%(P<0.001);10ngU-Ⅱ组在6h使眼压降低54.7%(P<0.001);100ngU-Ⅱ组在6h使眼压降低56.4%(P<0.001)。四组降眼压作用分别持续24h;2,3,4d。结论:U-Ⅱ具有快速、强效、持久的降低眼压的作用,有可能成为防治青光眼的有效药物。 AIM: To study the effect of Urotensin Ⅱ (U-Ⅱ) on intraocular pressure(lOP). METHODS: Different concentrations of U- Ⅱ (10pg/μL, 100pg/μL,lng/μL, 10ng/μL) were injected into anterior vitreous body of eyes in New Zealand rabbits. Schiotz impression tonometer were used with double balances after 0,1 hour;2,4,6,8,10,12,24,36 hours;2,3,4,5,6 days. RESULTS: lOP decreased 17.5%, 33.7%, 54.7% and 56.4%(P〈0.001) in groups of 0.1rig U-Ⅱ, 1ng U-Ⅱ, 10ng U-Ⅱ and 100ng U-Ⅱ after 10-12 hours, 8 hours, 6 hours and 6 hours respectively; The effects of lOP decreases continued until 24 hours; 2, 3, 4 days respectively. CONCLUSION: U-Ⅱ can decrease intraocular (IOP) rapidly,intensively and continuously. U- Ⅱ biological activity substance may become an medicine to prevent and treat glaucoma. pressure ,the new effective
出处 《国际眼科杂志》 CAS 2011年第8期1334-1336,共3页 International Eye Science
基金 中国福建省中医药重点科研资助项目(No.Wzz-b0601)~~
关键词 尾加压素Ⅱ 眼压 青光眼 Urotensin Ⅱ intraocular pressure glaucoma rabbit
  • 相关文献

参考文献7

二级参考文献40

  • 1Matsushita M, Shichiri M, Fukai N, et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line. Endocrinol 2003 ; 144 (5) : 1825-1831.
  • 2Maguire JJ, Kue RE, Davenport AP. Ophen-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131 (3) :441-446.
  • 3Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin-II with mildly oxidized LDL on DNA synthesis on vascular smooth muscle ceils. Circulation 2001 ;4( 1 ) :16-18.
  • 4Matsushita M, Shichiri M, Fukai N, et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line. Endocrinology 2003 ; 144 ( 5 ) : 1825-1831.
  • 5Maguire JJ, Kue RE, Davenport AP. Ophen-receptor ligand human urotensin II : receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131 (3) :441-446.
  • 6Ames R S,Sarau H M,Chambers J K,et al.Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J].Nature,1999,401(6750):282-6.
  • 7Pelletier G,Lihrmann I,Dubessy C,et al.Androgenic down-regulation of urotensin Ⅱ precursor,urotensin Ⅱ-related peptide precursor and androgen receptor mRNA in the mouse spinal cord[J].Neuroscience,2005,132(3):689-96.
  • 8Egginger J G,Calas A.A novel hypothalamic neuroendocrine peptide:URP (urotensin-Ⅱ-related peptide)?[J].CR Biol,2005,328(8):724-31.
  • 9Lin Y,Tsuchihashi T,Matsumura K,et al.Central cardiovascular action of urotensin Ⅱ in conscious rats[J].J Hypertens,2003,21(1):159-65.
  • 10Lin Y,Tsuchihashi T,Matsumura K,et al.Central cardiovascular action of urotensin Ⅱ in spontaneously hypertensive rats[J].Hypertens Res,2003,26(10):839-4.

共引文献21

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部